Galapagos NV (GLPG) Financial Analysis & Valuation | Quarter Chart
Galapagos NV (GLPG)
GLPGPrice: $28.39
Fair Value: 🔒
🔒score
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoi... more
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and co... more
Description
Shares
| Market Cap | $1.87B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | BE | CEO | Henry Gosebruch |
| IPO Date | 2012-02-27 | CAGR | 0.27% |
| Employees | 704 | Website | www.glpg.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
GLPG chart loading...
Fundamentals
Technicals
| Enterprise Value | $1.70B | P/E Ratio | 3.27 |
| Forward P/E | -20.32 | PEG Ratio | — |
| P/S Ratio | 1.58 | P/B Ratio | 0.5 |
| P/CF Ratio | -5.63 | P/FCF Ratio | -5.46 |
| EPS | $8.68 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 262.17% | Gross Margin | 0.98% |
| Operating Margin | 0.36% | Profit Margin | 0.47% |
| ROE | 0.17% | ROA | 0.14% |
| ROCE | 0.12% | Current Ratio | 30.48 |
| Quick Ratio | 30.3 | Cash Ratio | 0.67 |
| Debt/Equity | 0 | Interest Coverage | 171.26 |
| Altman Z Score | 9.78 | Piotroski Score | 4 |